Cargando…

The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis

BACKGROUND: In 2019, Chinese government implemented volume-based procurement of 25 drugs in 4 municipalities and 7 sub-provincial cities, i.e. “4 + 7” policy. Competitive bidding was conducted by the government based on the annual agreed procurement volume submitted by each public medical institutio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ying, Chen, Lei, Ke, Xinfeng, Mao, Zongfu, Zheng, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265121/
https://www.ncbi.nlm.nih.gov/pubmed/34238290
http://dx.doi.org/10.1186/s12913-021-06698-5
_version_ 1783719706482442240
author Yang, Ying
Chen, Lei
Ke, Xinfeng
Mao, Zongfu
Zheng, Bo
author_facet Yang, Ying
Chen, Lei
Ke, Xinfeng
Mao, Zongfu
Zheng, Bo
author_sort Yang, Ying
collection PubMed
description BACKGROUND: In 2019, Chinese government implemented volume-based procurement of 25 drugs in 4 municipalities and 7 sub-provincial cities, i.e. “4 + 7” policy. Competitive bidding was conducted by the government based on the annual agreed procurement volume submitted by each public medical institution in pilot cities. Pilot cities were required to implement bid winning results in March 2019 and the use volume of bid winning products was examined to ensure the completion of agreed procurement volume. In the policy, an oral antibiotic (cefuroxime) was included. Given the current condition of the irrational use of antibiotics in China, this study aims to evaluate the impact of “4 + 7” policy on the use of policy-related antibiotics. METHODS: This study used drug purchase data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. Oral antibiotic drugs related to “4 + 7” policy were selected as study samples, including cefuroxime and 12 antibiotic drugs that have an alternative relationship with cefuroxime in clinical use. Purchase volume and expenditures were selected as outcome variables, and were measured using Defined Daily Doses (DDDs) and Chinese yuan, respectively. Segmented linear regression analysis with interrupted time series was adopted to examine the effect of “4 + 7” policy. RESULTS: After the implementation of “4 + 7” policy, the overall volume of cefuroxime and its alternative drugs increased from 9.47 million DDDs to 13.42 million DDDs, with an increase of 41.8 %. The results of segmented linear regression showed that the volume of cefuroxime significantly increased 161.16 thousand DDDs after “4 + 7” policy (95 % CI: 59.43 to 262.90, p-value = 0.004). The volume of alternative drugs significantly increased 273.65 thousand DDDs (95 % CI: 90.17 to 457.12, p-value = 0.006). The overall “4 + 7” policy-related antibiotics significantly increased 436.31 thousand DDDs (95 % CI: 190.81 to 681.81, p-value = 0.001) after “4 + 7” policy. CONCLUSIONS: This study provides evidence that the implementation of “4 + 7” volume-based procurement policy was associated with significant increases in the volume of policy-related antibiotic drugs. The increase in antibiotic use after the policy needs special attention and vigilance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-021-06698-5.
format Online
Article
Text
id pubmed-8265121
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82651212021-07-08 The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis Yang, Ying Chen, Lei Ke, Xinfeng Mao, Zongfu Zheng, Bo BMC Health Serv Res Research BACKGROUND: In 2019, Chinese government implemented volume-based procurement of 25 drugs in 4 municipalities and 7 sub-provincial cities, i.e. “4 + 7” policy. Competitive bidding was conducted by the government based on the annual agreed procurement volume submitted by each public medical institution in pilot cities. Pilot cities were required to implement bid winning results in March 2019 and the use volume of bid winning products was examined to ensure the completion of agreed procurement volume. In the policy, an oral antibiotic (cefuroxime) was included. Given the current condition of the irrational use of antibiotics in China, this study aims to evaluate the impact of “4 + 7” policy on the use of policy-related antibiotics. METHODS: This study used drug purchase data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. Oral antibiotic drugs related to “4 + 7” policy were selected as study samples, including cefuroxime and 12 antibiotic drugs that have an alternative relationship with cefuroxime in clinical use. Purchase volume and expenditures were selected as outcome variables, and were measured using Defined Daily Doses (DDDs) and Chinese yuan, respectively. Segmented linear regression analysis with interrupted time series was adopted to examine the effect of “4 + 7” policy. RESULTS: After the implementation of “4 + 7” policy, the overall volume of cefuroxime and its alternative drugs increased from 9.47 million DDDs to 13.42 million DDDs, with an increase of 41.8 %. The results of segmented linear regression showed that the volume of cefuroxime significantly increased 161.16 thousand DDDs after “4 + 7” policy (95 % CI: 59.43 to 262.90, p-value = 0.004). The volume of alternative drugs significantly increased 273.65 thousand DDDs (95 % CI: 90.17 to 457.12, p-value = 0.006). The overall “4 + 7” policy-related antibiotics significantly increased 436.31 thousand DDDs (95 % CI: 190.81 to 681.81, p-value = 0.001) after “4 + 7” policy. CONCLUSIONS: This study provides evidence that the implementation of “4 + 7” volume-based procurement policy was associated with significant increases in the volume of policy-related antibiotic drugs. The increase in antibiotic use after the policy needs special attention and vigilance. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-021-06698-5. BioMed Central 2021-07-08 /pmc/articles/PMC8265121/ /pubmed/34238290 http://dx.doi.org/10.1186/s12913-021-06698-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Ying
Chen, Lei
Ke, Xinfeng
Mao, Zongfu
Zheng, Bo
The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
title The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
title_full The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
title_fullStr The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
title_full_unstemmed The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
title_short The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018–2019: an interrupted time-series analysis
title_sort impacts of chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in shenzhen, 2018–2019: an interrupted time-series analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265121/
https://www.ncbi.nlm.nih.gov/pubmed/34238290
http://dx.doi.org/10.1186/s12913-021-06698-5
work_keys_str_mv AT yangying theimpactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis
AT chenlei theimpactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis
AT kexinfeng theimpactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis
AT maozongfu theimpactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis
AT zhengbo theimpactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis
AT yangying impactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis
AT chenlei impactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis
AT kexinfeng impactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis
AT maozongfu impactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis
AT zhengbo impactsofchinesedrugvolumebasedprocurementpolicyontheuseofpolicyrelatedantibioticdrugsinshenzhen20182019aninterruptedtimeseriesanalysis